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Abstract
Background: Docetaxel monotherapy is one of the standard treatments for non-small-cell lung cancer in elderly
patients. The addition of bevacizumab to docetaxel seems promising; however, the feasibility of this combination
has not been investigated in such patients.
Methods: Patients with advanced non-squamous non-small-cell lung cancer aged 70 years or older who had not
previously received cytotoxic chemotherapy were enrolled. Patients in the Level 0 cohort received docetaxel
60 mg/m2 and bevacizumab 15 mg/kg, whereas those in the Level-1 cohort received docetaxel 50 mg/m2 and
bevacizumab 15 mg/kg. Chemotherapy was repeated 3 weekly for six cycles. The primary endpoint was toxicity and
the secondary endpoints were response rate, progression-free survival, overall survival, and proportion of patients
who underwent three or more cycles of chemotherapy.
Results: Twenty-one patients were enrolled from December 2010 to September 2012 at six institutes. Of the nine
patients enrolled in Level 0, two experienced dose-limiting toxicity (febrile neutropenia and prolonged Grade 4
neutropenia in one patient, and Grade 3 infection in another patient) during the first cycle. Enrollment to the Level
0 cohort was terminated because two patients developed Grade 4 sepsis during later cycles. The remaining 12
patients were enrolled in the Level-1 cohort, in which two dose-limiting toxicities (prolonged Grade 4 neutropenia
and Grade 3 increased aminotransferase level) were observed. No patient in the Level-1 cohort experienced Grade
4 nonhematologic toxicity. Grade 4 neutropenia occurred in 89 % of Level 0 patients and 50 % of Level-1 patients.
The proportion of patients who experienced Grade 3/4 infection, febrile neutropenia or sepsis was 44 % in the
Level 0 cohort, and 8 % in the Level-1 cohort. The overall response rate to chemotherapy and progression-free
survival were 29 % (95 % CI, 11–52 %) and 5.9 months (95 % CI, 3.6–9.1 months), respectively. Efficacy outcomes did
not differ significantly between the cohorts.
Conclusions: Toxicities were tolerable in level-1 cohort. The recommended dose of combination chemotherapy
with docetaxel and bevacizumab for elderly patients was determined as 50 mg/m2 of docetaxel and 15 mg/kg of
bevacizumab and toxicities were tolerable. Further studies are warranted.
Trial registration: UMIN Clinical Trial Registry; UMIN000004240.
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Background
Lung cancer is the leading cause of cancer-related mor-
tality, with over 1.3 million people dying annually from
lung cancer worldwide [1]. In Japan, approximately two
thirds of cases of newly diagnosed lung cancer occur in
patients aged greater than 70 years [2], and the propor-
tion of older patients with lung cancer continues to in-
crease [3]. Older patients tend to have reduced bone
marrow and hepatic and renal function compared to
younger patients, which is likely a key determinant in
the potential for increased adverse effects in response to
anticancer chemotherapies [4]. Since studies have shown
that older patients with NSCLC have higher rates of tox-
icities and complications related to treatment with plat-
inum drugs [5, 6], the standard treatment approach for
older patients may be different than that for younger
patients.
A randomized trial comparing vinorelbine with best
supportive care (the Elderly Lung Cancer Vinorelbine
Italian [ELVIS] study) [7] and another three-arm trial
evaluating vinorelbine, gemcitabine, and a combination
of those two drugs (the Multicenter Italian Lung Cancer
in the Elderly [MILES] study) [8] have demonstrated that
monotherapy is effective in elderly patients with NSCLC.
The West Japan Thoracic Oncology Group (WJTOG)
9904 study found that docetaxel monotherapy results in
a trend toward longer survival compared with vinorelbine
monotherapy in patients aged 70 years or older with ad-
vanced NSCLC [9]; this finding has been supported by a
similar study conducted by the Hellenic Oncology
Research Group [10]. In elderly patients, carboplatin-
paclitaxel resulted in significantly longer overall survival
(OS) than vinorelbine or gemcitabine in the recent Inter-
groupe Francophone de Cancérologie Thoracique (IFCT)
0501 trial [11]. The current standard therapy for elderly
patients with NSCLC is platinum doublet. Since a direct
comparison between docetaxel and carboplatin-paclitaxel
has not been conducted in the setting of a large random-
ized trial and a Japanese randomized phase 2 trial did not
show a significant difference in OS [12], docetaxel mono-
therapy remains an optional treatments for NSCLC in eld-
erly patients.
Bevacizumab, an anti-vascular endothelial growth fac-
tor antibody, exerts antitumor activity by inhibiting
angiogenesis [13] and by improving drug delivery by
lowering the interstitial pressure within the tumor [14].
The Eastern Cooperative Oncology Group (ECOG) dem-
onstrated a significant survival advantage with the
addition of bevacizumab to carboplatin-paclitaxel in a
randomized phase III trial [15]. However, a large retro-
spective study [16] and a subset analysis of the ECOG
4599 study [17] have shown no significant benefit in
adding bevacizumab to carboplatin-paclitaxel in patients
aged ≥65 years. Despite these findings, the value of
incorporating bevacizumab into chemotherapy for older
patients remains unclear due to the lack of prospective
randomized trials with sufficient statistical power. In our
study, we seek to further investigate the combination of
docetaxel and bevacizumab in an elderly patient popula-
tion with NSCLC. The goal of this multi-center study is
to evaluate the tolerability of the combination and to es-
tablish the appropriate dosage in elderly patients with
NSCLC.
Although the toxicity profile of bevacizumab differs
between older and younger patients [16], no study has
evaluated the tolerability of docetaxel-bevacizumab in
older patients. Therefore, the goal of this multi-center
study was to evaluate this combination’s tolerability and
to determine the appropriate dosage in older patients
with NSCLC.
Methods
This multi-center, open-label, dose-finding study was
conducted in accordance with the Declaration of
Helsinki and the Ethical Guidelines for Clinical Research
issued by the Japanese Ministry of Health, Labour and
Welfare. The protocol was approved by the Clinical Trial
Review Committee of the Thoracic Oncology Research
Group and the Institutional Review Board or Ethics
Committee of each participating center. All patients pro-
vided written informed consent. The clinical trial regis-
try number was UMIN000004240.
Study participants
Eligible patients were aged ≥70 years and had stage IIIB/
IV or recurrent non-squamous NSCLC. No patient had
received prior cytotoxic chemotherapy; however, prior
treatment with an epidermal growth factor receptor tyro-
sine kinase inhibitor (EGFR-TKI) was allowed. Uracil-
tegafur therapy as adjuvant chemotherapy for Stage I
NSCLC was also allowed. Additional inclusion criteria
were ECOG performance status (PS) of 0 or 1, at least one
measurable focus of disease, neutrophil count ≥2,000
cells/μL, hemoglobin ≥9.5 g/dL, platelet count ≥100,000
cells/μL, aspartate aminotransferase and alanine amino-
transferase (ALT) levels ≤2.5× the upper limit of normal,
total bilirubin level ≤1.5× the upper limit of normal, serum
creatinine level ≤1.2 mg/dL, oxygen saturation by pulse
oximetry ≥93 %, proteinuria ≤1+, and life expectancy lon-
ger than 12 weeks.
Patients were excluded if they had undergone any sur-
gery within the past 8 weeks, exploratory thoracotomy
within the last 4 weeks, or radiotherapy or minor proce-
dures (for example, fluid drainage with a chest tube)
within the last 2 weeks before enrollment. Other major
exclusion criteria were a history of hemoptysis, a history
of peptic ulcer within the past year, severe or uncontrol-
lable comorbidities, brain metastases, massive pleural/
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pericardial effusion or ascites, regular use of anticoagu-
lants (≤325 mg per day of aspirin was permitted), or
concomitant malignancy.
Procedures
Eligible patients were given docetaxel and bevacizumab
intravenously and the treatment was repeated every
3 weeks. Patients in the Level 0 cohort received doce-
taxel 60 mg/m2 (the recommended dose for monother-
apy in Japan) and bevacizumab 15 mg/kg, and those in
the Level -1 cohort received docetaxel 50 mg/m2 and
bevacizumab 15 mg/kg. In each cohort, if less than four
of the first six patients had experienced dose-limiting
toxicity (DLT), an additional six patients were to be en-
rolled in the same cohort. If four or more of the first six
patients in the Level 0 cohort had experienced DLT, the
study was to proceed to Level -1. If four or more of the
first six patients in the Level-1 cohort had experienced
DLT, the study was to be terminated. Overall toxicity
was evaluated after the treatment of 12 patients in a
given cohort. If six or more of the 12 patients in the
Level 0 cohort had experienced DLT, the study was to
proceed to Level-1.
DLT was defined as the following toxicities occurring
in the first cycle: Grade 4 neutropenia lasting 4 days or
more, febrile neutropenia, Grade 4 thrombocytopenia,
non-hematological toxicities ≥Grade 3 (except for nau-
sea, hyponatremia, weight loss, anorexia, infusion reac-
tion, and hypertension), or Grade 4 hypertension. The
recommended dose for future study was determined by
the overall toxicities, including all of the adverse events
occurring during treatment. Primary prophylactic use of
granulocyte colony-stimulating factor (G-CSF) was not
allowed. G-CSF administration was recommended for
patients with Grade 4 neutropenia or Grade 4 leukopenia,
this being determined by the availability of coverage
by Japanese public health insurance. Although this
trial defined study treatment as six cycles of docetaxel
plus bevacizumab, any subsequent therapies, including
continuation of docetaxel and/or bevacizumab, were
allowed.
Assessments
Toxicities were evaluated according to the National
Cancer Institute’s Common Toxicity Criteria for Adverse
Events, version 4.0. Complete blood counts and serum
chemistries were obtained at the beginning of each cycle,
and weekly during the first cycle.
Tumor response to the chemotherapy was assessed
using the Response Evaluation Criteria in Solid Tumors,
version 1.1. After baseline evaluation, tumor status was
assessed every 6 weeks (two cycles). Two consecutive
evaluations were required to confirm complete response
or partial response to the chemotherapy.
Statistical methods
The primary objectives were to evaluate the toxicity pro-
file and to determine the recommended dose of
docetaxel-bevacizumab therapy in patients aged 70 years
or older with non-squamous NSCLC. The secondary
endpoints were the response rate to chemotherapy,
progression-free survival (PFS), OS, and the proportion
of patients who underwent three or more cycles of
chemotherapy. PFS was defined as the number of
months between enrollment and date of disease progres-
sion or death. Patients who remained alive without dis-
ease progression at the end of follow-up, and patients
who had started subsequent chemotherapy without dis-
ease progression, were censored. OS was defined as the
number of months between study enrollment and date
of death. Patients alive at the end of follow-up were cen-
sored. Differences in proportions between the cohorts
were evaluated using the χ2 test. Differences in age were
compared using the Student’s t-test. PFS and OS were
estimated using the Kaplan–Meier method, and the log-
rank test was used for inter-group comparisons. All tests
were two-sided with a significance level of 0.05.
Results
Patient characteristics
From December 2010 to September 2012, 21 patients
with stage IIIB/IV or recurrent non-squamous NSCLC
were enrolled at six institutes. Nine patients were en-
rolled in the Level 0 cohort (docetaxel 60 mg/m2, beva-
cizumab 15 mg/kg) and subsequently 12 were enrolled
in the Level-1 cohort (docetaxel 50 mg/m2, bevacizumab
15 mg/kg). The median age was 75 years (range, 70–84
years), and 12 patients (57 %) were female. Most patients
had adenocarcinoma (90 %) and stage IV disease (86 %).
EGFR mutations were detected in four patients (19 %).
ECOG-PS was zero in eight patients (38 %) and one in
13 patients (62 %). Three patients (14 %) had received
prior EGFR-TKI therapy; all three had an EGFR-
activating mutation. One patient (5 %) had undergone
adjuvant chemotherapy with uracil-tegafur after complete
resection of Stage I NSCLC. Baseline characteristics did
not differ significantly between the two cohorts (Table 1).
Treatment and safety
Nine patients received cycles of 60 mg/m2 of docetaxel
and 15 mg/kg of bevacizumab (Level 0). The median
number of cycles delivered was four, 78 % of patients
underwent three or more cycles. Two patients (22 %)
completed six cycles of chemotherapy. The reasons for
terminating chemotherapy were adverse events in five
patients (56 %) and disease progression in two (22 %).
One patient required dose reduction of docetaxel due
to neutropenia, and five patients experienced delays
in treatment. The reasons for treatment delay were
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administrative (e.g., public holidays) or to suit patients’
schedules, except in the case of one patient with pro-
longed neutropenia.
DLT, which was evaluated in the first cycle, occurred
in two patients in the Level 0 cohort: one patient devel-
oped febrile neutropenia and Grade 4 neutropenia last-
ing for more than 4 days and the other patient had
Grade 3 infection. In addition, two other patients devel-
oped Grade 4 sepsis during later cycles. The first patient
with severe sepsis was a 75-year-old man who developed
Grade 4 neutropenia (280 cells/μL) on day 11 of the
fourth cycle and subsequently fever (39.3 °C) and septic
shock on day 12. He recovered after treatment with
intravenous cefepime, G-CSF, and dopamine. The sec-
ond patient was a 74-year-old woman who developed
Grade 4 neutropenia (100 cells/μL), fever of 40.0 °C,
hypoxemia, and septic shock: blood cultures revealed
Escherichia coli and Klebsiella pneumoniae. She recov-
ered after treatment with intravenous cefepime, G-CSF,
and dopamine. Due to the life-threatening events in
these two cases, enrollment was stopped by the Data
and Safety Monitoring Board (DSMB). After detailed
examination of the treatment course of these two pa-
tients and other identified toxicities, the DSMB recom-
mended terminating enrollment in the Level 0 cohort
and continuing the trial with the Level-1 cohort.
Twelve patients were given 50 mg/m2 of docetaxel and
15 mg/kg of bevacizumab (Level-1). The median number
of cycles delivered was four; 75 % of patients underwent
three or more cycles. Three patients (25 %) completed
six cycles of chemotherapy. The reasons for terminating
chemotherapy were patients’ decision in four patients,
adverse events in three, and disease progression in two.
DLT occurred in two patients in the Level-1 cohort; one
patient developed Grade 4 neutropenia lasting for more
than 4 days and the other patient experienced a Grade 3
increase in the ALT level. No Grade 4 non-hematologic
toxicity was observed in this cohort and thus the recom-
mended dose for a future trial was determined as
50 mg/m2 of docetaxel and 15 mg/kg of bevacizumab.
Four patients required delays in treatment due to pro-
longed neutropenia, and six patients experienced admin-
istrative delays. No treatment-related deaths occurred
throughout the study.
Toxicity profiles of each cohort are shown in Table 2
(Level 0) and Table 3 (Level-1), respectively. Neutro-
penia and leukocytopenia were frequently observed,
more patients tending to develop Grade 4 neutropenia
in the Level 0 (89 %) than in the Level-1 cohort
(50 %, p = 0.051). All patients (100 %) in Level 0 and
83 % in Level-1 developed hematological toxicities ≥
Grade 3. Grade 3/4 infection, febrile neutropenia, and
Table 1 Patient characteristics
Category Subcategory Level 0, N Level -1, N
Total 9 12
Median age (range), yr 78 (74–79) 75 (70–84)
Sex Female 5 7
Male 4 5
Histological type Adenocarcinoma 8 11
NSCLC, NOS 1 1
Disease stage IIIB 1 1
IV 8 10
Recurrent 0 1
Performance status 0 3 5
1 6 7
EGFR mutation Ex19 del 0 2
L858R 2 0
Wild type 5 7
Unknown 2 3
EGFR: Epidermal growth factor receptor, Ex19del: Exon 19 deletions, NOS: Not
otherwise specified, NSCLC: Non-small-cell lung cancer
Table 2 Toxicities in Level 0 cohort
Toxicity G1, % G2, % G3, % G4, %
Hematologic
Neutropenia 0 0 11 89
Leukopenia 0 11 56 33
Anemia 56 22 0 0
Thrombocytopenia 56 11 0 0
Nonhematologic
AST increased 33 0 11 0
ALT increased 33 0 11 0
Anorexia 11 33 22 0
Stomatitis 11 22 11 0
Nausea 11 33 0 0
Diarrhea 22 22 0 0
Vomiting 22 11 0 0
Allergic reaction 22 11 0 0
Hypertension 0 11 0 0
Dyspnea 0 11 0 0
Peripheral neuropathy 44 0 0 0
Constipation 33 0 0 0
Edema limbs 22 0 0 0
Weight loss 11 0 0 0
Febrile neutropenia - - 11 0
Infection 0 0 11 0
Sepsis - - - 22
Hypoxia - 0 11 0
ALT: Alanine aminotransferase, AST: aspartate aminotransferase, G: Grade
(according to the National Cancer Institute’s Common Toxicity Criteria for
Adverse Events, version 4.0)
Takagi et al. BMC Cancer  (2015) 15:740 Page 4 of 7
sepsis were also marginally more frequent in the
Level 0 cohort (44 %) compared to the Level-1 cohort
(8 %, p = 0.051). In the Level 0 cohort, 56 % of patient de-
veloped Grade 3 nonhematological toxicities, and the pro-
portion in the Level -1 cohort was 58 %. G-CSF was
administered to 89 % of patients in the Level 0 cohort and
58 % of patients in the Level-1 cohort.
Efficacy
The overall response rate to chemotherapy was 29 %
(95 % confidence interval [CI], 11–52), and the disease
control rate was 71 % (95 % CI, 48–89). At a median
follow-up time of 12.2 months, the median PFS and OS
were 5.9 months (95 % CI, 3.6–9.1) and 18.3 months
(95 % CI, 7.7 months to not reached), respectively
(Fig. 1). OS was not mature: only 43 % of events had oc-
curred at the time of analysis.
For the Level 0 cohort, response rate, median PFS, and
median OS were 33 %, 4.7 months, and 11.0 months, re-
spectively, and for the Level-1 cohort, 25 %, 8.7 months,
and 18.3 months, respectively. Response rates did not
differ significantly between the two cohorts (Fig. 2). Al-
though PFS and OS appeared longer in the Level-1
cohort, the differences were not statistically significant
(p = 0.11 and p = 0.44, respectively).
Disease progression was observed in 17 patients. Of
these, nine (53 %) underwent subsequent chemotherapy,
including pemetrexed in five patients and gefitinib in two.
Discussion
This is the first dose-finding study evaluating the com-
bination of docetaxel/bevacizumab therapy in older pa-
tients with non-squamous NSCLC. The addition of
bevacizumab to 60 mg/m2 of docetaxel was not tolerated
from the toxicity standpoint. The older patients in our
study experienced a significantly higher incidence of tox-
icities with the addition of bevacizumab compared to
what has been noted in younger patients, which is likely
a reflection of decreased organ function and increased
vulnerability to infection in older patients.
Of the nine patients who received 60 mg/m2 of doce-
taxel and 15 mg/kg of bevacizumab, eight (89 %) devel-
oped Grade 4 neutropenia, four (44 %) developed severe
Table 3 Toxicities in Level-1 cohort
Toxicity G1, % G2, % G3, % G4, %
Hematologic
Neutropenia 8 8 25 50
Leukopenia 17 25 50 8
Anemia 58 8 8 0
Thrombocytopenia 25 8 0 0
Nonhematologic
AST increased 17 0 0 0
ALT increased 17 0 8 0
Anorexia 25 42 8 0
Nausea 42 8 8 0
Diarrhea 17 17 8 0
Vomiting 8 0 8 0
Stomatitis 25 17 0 0
Constipation 58 8 0 0
Fatigue 42 8 0 0
Hypertension 8 8 0 0
Peripheral neuropathy 8 8 0 0
Weight loss 17 0 0 0
Arthralgia 8 0 0 0
Febrile neutropenia - - 8 0
Intracranial hemorrhage 0 0 8 0
ALT: alanine aminotransferase, AST: aspartate aminotransferase, G: Grade
(according to the National Cancer Institute’s Common Toxicity Criteria for
Adverse Events, version 4.0)
Fig. 1 Kaplan-Meier curves for progression-free survival a and overall
survival b
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infection or febrile neutropenia, and two (22 %) devel-
oped life-threatening sepsis. Primary prophylactic G-CSF
was not allowed in this trial because only 12.5 % of pa-
tients had developed febrile neutropenia in a previous
Japanese phase III trial of docetaxel therapy in older pa-
tients [9]. Even taking the absence of primary prophylac-
tic G-CSF into consideration, the toxicities observed in
the Level 0 cohort were not acceptable in older patients.
A previous Japanese phase III trial in which patients
aged 70 years or older with advanced NSCLC were treated
with 60 mg/m2 of docetaxel reported Grade 4 neutropenia
in 56.8 % of patients and febrile neutropenia in 12.5 % [9].
Pre-clinical studies have shown that bevacizumab en-
hances the efficacy of docetaxel [16, 18]. A subset analysis
of elderly participants enrolled in the ECOG 4599 study
[17] showed that when bevacizumab was added, more
patients tended to have severe toxicities including Grade 4
neutropenia. A meta-analysis also showed that addition of
bevacizumab to cytotoxic chemotherapy was associated
with a higher incidence of neutropenia ≥Grade 3 and
febrile neutropenia [16]. These findings help explain the
relatively higher incidence of neutropenia and infection
observed in the Level 0 cohort in this study.
By contrast, treatment with 50 mg/m2 of docetaxel
and 15 mg/kg of bevacizumab was much better tolerated
than 60 mg/m2 of docetaxel alone. Neutropenia and in-
fection in the Level-1 cohort were relatively less frequent
than those in historical cohort with docetaxel monother-
apy [9], and no Grade 4 non-hematological toxicity oc-
curred in Level-1 cohort. In previous IFCT-0501 study
[11], the hematological toxicity of carboplatin and
weekly paclitaxel regimen was similar in the present
Level-1 cohort, with neutropenia (≥Grade3) and febrile
neutropenia occurring in 48.4 and 9.4 % of the patients,
respectively. On the other hand, they observed treatment-
related deaths in 4.4 % of the patients, whereas no
treatment-related deaths occurred in the present study.
Although the sample size was limited because of the na-
ture of this being a feasibility study, data from the Level-1
cohort in this trial support the feasibility of treatment with
50 mg/m2 of docetaxel and 15 mg/kg of bevacizumab for
older patients with advanced non-small cell lung cancer.
Despite that the usual dose of docetaxel in NSCLC is
75 mg/m2 in most countries, a Japanese phase I study has
determined a recommended dose of docetaxel monother-
apy for NSCLC of 60 mg/m2, the DLT having been
neutropenia [19]. The adequacy of this lower dose for
Asian patients has been validated by a randomized trial in
China comparing two doses [20]. Our study noted a sig-
nificantly increased incidence of neutropenia with the
addition of bevacizumab, which supports the notion that
the addition of bevacizumab results in a lower tolerable
dose of docetaxel. [16]. Further, elderly patients have poorer
bone marrow function compared to younger patients and
also seem to be more vulnerable to infectious diseases.
The key limitation of this study was that the recom-
mended dose was not determined on the basis of DLTs
observed in the first cycle but was instead determined by
toxicities observed in later cycles. The goal of this study
was to determine the appropriate dose of combination
therapy with docetaxel and bevacizumab for use in fu-
ture studies. Another justification for this dose is that
this regimen has the potential to be adapted to daily
practice. One more limitation of this study was that two
populations are mixed in this trial, EGFR wild-type and
EGFR-mutants. This might be a bias of the study.
The antitumor efficacy did not differ significantly be-
tween the two doses of combination docetaxel and
Fig. 2 Waterfall plot of best percent change in target lesions in each cohort. BV, bevacizumab; DTX, docetaxel
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bevacizumab chemotherapy, and equivalent to the previ-
ous studies [20]; however, the sample size was too small
to compare efficacy outcomes. Additionally, because eli-
gibility for bevacizumab is in itself a strong predictor of
better prognosis [21], we are not able to draw any defin-
ite conclusions about the efficacy of these regimens in
elderly patients.
Conclusions
The recommended dose of docetaxel in combination
with 15 mg/kg of bevacizumab for elderly patients was
determined to be 50 mg/m2. Toxicities related to
chemotherapy in elderly patients are often different from
those seen in younger patients and warrant vigilant at-
tention. A randomized trial comparing docetaxel plus
bevacizumab with pemetrexed plus bevacizumab in eld-
erly patients with NSCLC is ongoing.
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